Your session is about to expire
← Back to Search
CL20-i4-EF1α-hγc-OPT for Severe Combined Immunodeficiency (LVXSCID-ND Trial)
LVXSCID-ND Trial Summary
This trial is testing a new way to treat SCID-X1, a genetic disorder that prevents the development of a functioning immune system. The new method, called lentiviral gene transfer, involves transferring a normal copy of the common gamma chain gene into the patient's bone marrow stem cells. The investigators want to determine if the procedure is safe and effective.
- X-Linked Severe Combined Immunodeficiency (SCID)
LVXSCID-ND Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowLVXSCID-ND Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2021 Phase 2 trial • 22 Patients • NCT01203020LVXSCID-ND Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Are patients still being enrolled in this research project?
"Yes, as of now this study is still recruiting patients. The clinical trial was initially posted on August 17th, 2016 and updated January 5th, 2022. They are looking for a total of 28 patients that will be split between 3 locations."
What are the results of using CL20-i4-EF1α-hγc-OPT for treating patients?
"CL20-i4-EF1α-hγc-OPT can be an effective treatment for various conditions including allogeneic hematopoietic stem cell transplant, chronic myelogenous leukemia, conditioning regimens for allogeneic stem cell transplantation therapy, and thrombocythemia, essential."
How many individuals are taking part in this test?
"The clinical trial is accepting patients at this time, as evidenced by information available on clinicaltrials.gov. This research was originally posted on 8/17/2016 and updated most recently on 1/5/2022. The study requires 28 individuals from 3 different locations."
Are there any similar treatments to CL20-i4-EF1α-hγc-OPT that have been looked into?
"Currently, there are one hundred and four independent clinical trials assessing the efficacy of CL20-i4-EF1α-hγc-OPT. Of these investigations, thirteen have progressed to Phase 3. Most of the related research is emanating out of Philadelphia, Pennsylvania; although, there are 1072 locations running clinical trials for CL20-i4-EF1α-hγc OPT globally."
Share this study with friends
Copy Link
Messenger